Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
Megan M OberleCarolyn T BramanteEric M BombergClaudia K FoxPaula M HaleAaron S KellyRashmi MamadiNandana PrabhuNina M Harder-LauridsenAmy C GrossPublished in: Pediatric obesity (2023)
This secondary analysis suggests that adolescents with obesity may experience significant BMI reductions after 56 weeks of liraglutide treatment, regardless of their sex, race, ethnicity, age, pubertal stage, glycemic status, obesity category, severity of depression symptoms, or weight variability. Early response may predict greater week 56 response.
Keyphrases
- weight loss
- placebo controlled
- weight gain
- bariatric surgery
- phase iii
- double blind
- type diabetes
- roux en y gastric bypass
- insulin resistance
- metabolic syndrome
- young adults
- gastric bypass
- physical activity
- phase ii
- body mass index
- glycemic control
- high fat diet induced
- clinical trial
- study protocol
- open label
- depressive symptoms
- sleep quality
- skeletal muscle
- data analysis